Go to deals
Healthcare | Private Equity

BioClin has been acquired by Trimb Healthcare

Orange Pearl International has sold BioClin, a leading healthcare products company, to Trimb Healthcare AB, a Swedish pharmaceutical company.

Based in the Netherlands, BioClin sells products to provide direct treatment and relief for women’s intimate health discomforts. The company’s product portfolio consists of Multi-Gyn, a complete range for treating intimate discomforts and Multi-Mam, a product range of self-care products for mothers and babies. BioClin’s brands are growing rapidly and are sold in pharmacies and drugstores in over 60 countries worldwide.

Trimb Healthcare is rapidly growing pharmaceutical company with a focus on sales, marketing and development of prescription-free OTC pharmaceuticals and consumer healthcare products.

Oaklins' team in the Netherlands acted as the exclusive sell-side advisor to the shareholders of BioClin in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Robert  Boersma

Robert Boersma

Partner

Amsterdam, Netherlands
Oaklins Netherlands
 Casper  Oude Essink

Casper Oude Essink

Senior Associate

Amsterdam, Netherlands
Oaklins Netherlands

Related deals

BlijWerkt has been acquired by Mentha Capital
Business Support Services | Healthcare | Private Equity

BlijWerkt has been acquired by Mentha Capital

Gilde Healthcare Partners has sold BlijWerkt Groep B.V. to Mentha Capital.

Learn more
Mentha Capital has raised financing for the acquisition of Blijwerkt and paraDIGMA
Business Support Services | Private Equity

Mentha Capital has raised financing for the acquisition of Blijwerkt and paraDIGMA

Mentha Capital has raised financing for the acquisition of Blijwerkt Groep B.V. and paraDIGMA.

Learn more
ACLM Fund has acquired Colas' Casablanca property
Private Equity | Real Estate

ACLM Fund has acquired Colas' Casablanca property

ACLM Fund has acquired 2.5 hectares of land in Casablanca from the Colas Group. The property will be developed, parceled and sold with a forecast IRR of 34%.

Learn more